Trials / Completed
CompletedNCT00665626
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- Rigel Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib disodium (R935788) | R935788 100 mg tablet, orally, twice-a-day |
| DRUG | Placebo | Placebo, orally, twice-a-day |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-04-24
- Last updated
- 2017-05-01
- Results posted
- 2016-07-15
Locations
44 sites across 7 countries: United States, Belgium, Colombia, France, Germany, Italy, Peru
Source: ClinicalTrials.gov record NCT00665626. Inclusion in this directory is not an endorsement.